Skip to main content
Premium Trial:

Request an Annual Quote

UnitedHealthcare to Cover Guardant360 for Approved CDx Indications in Lung, Breast Cancer

NEW YORK – Guardant Health said Wednesday that private health insurance firm UnitedHealthcare now covers the cost of the Guardant360 CDx assay for enrolled patients who fall under the test's US Food and Drug Administration-approved companion diagnostic indications. These include individuals with advanced lung and breast cancers.

Guardant360 CDx was approved by the FDA in 2020 for comprehensive genomic profiling of all solid tumors. The assay also has a growing slate of FDA-approved CDx indications, which currently includes four targeted therapies in non-small cell lung cancer and one in advanced breast cancer.

The test has been covered for Medicare beneficiaries, regardless of tumor type or CDx indication, since 2019.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.